Test Price
2,800 AED✅ Home Collection Available
KIF23 Gene Congenital Dyserythropoietic Anemia Type III Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, Available Daily 8 AM – 11 PM.
- Clinical Guidance: Complimentary Telephonic Post-Test Result Interpretation by DHA-Licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The KIF23 gene NGS test identifies pathogenic mutations causing Congenital Dyserythropoietic Anemia Type III (CDA III), a rare inherited red blood cell disorder characterized by ineffective erythropoiesis and morphological abnormalities of erythroblasts. This comprehensive genetic analysis aids in accurate diagnosis, family cascade screening, and personalized treatment planning. Our laboratory employs high-depth next-generation sequencing to interrogate all coding exons and flanking intronic regions, delivering precision and reliability for this clinically challenging condition.
| Feature | Our NGS Test | Traditional Single-Gene Test |
|---|---|---|
| Methodology | High-Depth NGS (Illumina NovaSeq X) | Sanger Sequencing (limited to known hotspots) |
| Coverage | 100% coding exons ±10 bp | Selected exons only |
| Sensitivity | 99.9% | ~85% |
| Turnaround Time | 21–28 Days | 28–42 Days |
| Price | 2,800 AED | ~2,500 AED |
Physician Insight & Safety Protocols
“Navigating a genetic diagnosis can be overwhelming, particularly for rare inherited anemias that require nuanced interpretation. This comprehensive KIF23 gene test sheds light on the underlying molecular etiology of your anemia, but it is essential to contextualize the results within your full clinical picture, family pedigree, and hematologic parameters. I am here to guide you through each step of variant classification and result communication, ensuring you feel supported throughout this journey.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Important Medication Advisory
⚠ Do not discontinue any prescribed medication without consulting your physician
Always inform your referring doctor and genetic counselor about all current medications, including over-the-counter supplements, before sample collection.
Safety Exclusion Criteria & Emergency Red Flags
- Active hemolytic crisis or acute systemic infection may compromise sample quality and should be resolved prior to testing.
- Recent blood transfusion (within 2 weeks) can interfere with germline DNA analysis due to donor-derived circulating DNA.
- If you experience sudden severe anemia, chest pain, signs of splenic infarction, or rapid clinical deterioration, seek emergency medical attention immediately before proceeding with testing.
Patient FAQ & Clinical Guidance
1. What is the KIF23 gene test and who should consider it?
This DNA test identifies pathogenic variants in the KIF23 gene responsible for Congenital Dyserythropoietic Anemia Type III, a rare autosomal dominant disorder. It is recommended for patients with unexplained hemolytic anemia, ineffective erythropoiesis, or a family history consistent with CDA III. It can also aid in carrier detection and prenatal counseling when appropriate.
2. How is the sample collected and what preparation is required?
A whole blood specimen (3–5 mL in EDTA) is drawn via VIP mobile phlebotomy at your home, or a finger-prick blood spot on an FTA card may be used. A mandatory pre-test genetic counseling session with a DHA-licensed geneticist is required to construct a detailed three-generation family pedigree, discuss inheritance patterns, and obtain informed consent. No specific medication or dietary restrictions are needed unless your physician advises otherwise.
3. When will results be available and how are they interpreted?
Results are typically delivered within 21 to 28 calendar days from sample receipt at our laboratory. A positive result confirms the molecular diagnosis of CDA III and guides personalized management, including surveillance for complications and family planning options. A negative result does not completely exclude the diagnosis if clinical suspicion remains high. Every report is reviewed and signed by our Consultant Medical Geneticist, who offers a complimentary telephonic consultation to explain the findings and their implications.
4. Can this test be performed during pregnancy or in children?
Yes, with appropriate genetic counseling and consent. For pediatric samples, a heel-prick blood spot on an FTA card is preferred. For prenatal diagnosis, amniocentesis or chorionic villus sampling is required and must be arranged through a maternal-fetal medicine specialist. Please discuss with your genetic counselor to determine the most appropriate approach for your situation.
UAE Regulatory & Data Privacy Adherence
This genetic testing service operates in full compliance with the UAE’s legislative framework for healthcare data protection. All patient genetic information is processed and stored under the provisions of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory maintains ISO 9001:2015 Certification (INT/EGQ/2509DA/3139) and is subject to regular audit by the Dubai Health Authority.
Your genetic data is encrypted, access-controlled, and never shared with third parties without your explicit written consent. You retain the right to access, rectify, and request deletion of your data as per applicable regulations.
Clinical & Logistical Metadata
| Test Name | KIF23 Gene Congenital Dyserythropoietic Anemia Type III Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 Days |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card Blood Spot |
| Methodology Used | High-Depth Next-Generation Sequencing (NGS) on Illumina NovaSeq X Platform |
| ICD-10-CM Code | D64.4 |
| LOINC Code | 81200-3 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians